

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Previously Presented) A polypeptide consisting of an immunogenic portion of a native WT1, wherein the polypeptide consists of the polypeptide set forth in SEQ ID NO:144.

2-5. (Canceled)

6. (Previously Presented) A polypeptide according to claim 1, wherein the polypeptide consists of 4-9 consecutive amino acids of SEQ ID NO:144.

7. (Previously Presented) A polypeptide according to claim 1, wherein the polypeptide consists of 8-9 consecutive amino acids of SEQ ID NO:144.

8-45. (Canceled)

46. (Withdrawn) The polypeptide of claim 1, wherein said immunogenic portion differs from SEQ ID NO:144 at between 1 and 3 amino acid positions, such that the ability of the polypeptide to react with WT1-specific antisera and/or T-cell lines or clones is enhanced relative to a native WT1.

47. (Previously Presented) A composition comprising the polypeptide of claim 1 in combination with a pharmaceutically acceptable carrier or excipient.

48. (Previously Presented) An immunogenic composition comprising the polypeptide of claim 1 in combination with a non-specific immune response enhancer.

49. (Previously Presented) The immunogenic composition according to claim 48 wherein the non-specific immune response enhancer preferentially enhances a T cell response in a patient.

50. (Previously Presented) The composition according to claim 48, wherein the immune response enhancer is selected from the group consisting of Montanide ISA50, Seppic Montanide ISA 720, a cytokine, a microsphere, dimethyl dioctadecyl ammoniumbromide (DDA) based adjuvants, AS-1, AS-2, Ribi Adjuvant system based adjuvant, QS21, saponin based adjuvants, Syntex adjuvant in its microfluidized form, MV, ddMV, immune stimulating complex (iscom) based adjuvants, and inactivated toxins.

51. (Previously Presented) The composition of claim 50, wherein said cytokine comprises GM-CSF.

52.-54. (Canceled)

55. (Withdrawn) The polypeptide of claim 52, wherein said immunogenic portion differs from WT1 at between 1 and 3 amino acid positions, such that the ability of the polypeptide to react with WT1-specific antisera and/or T-cell lines or clones is enhanced relative to a native WT1.

56. (Canceled)

57. (Previously Presented) An immunogenic composition comprising an isolated polypeptide comprising a WT1 polypeptide, wherein the WT1 polypeptide consists of no more than amino acids 1-249 of WT1 and comprises the amino acid sequence set forth in

SEQ ID NO:144 in combination with a non-specific immune response enhancer, wherein the non-specific immune response enhancer preferentially enhances a T cell response in a patient.

58. (Canceled)

59. (Previously Presented) The composition according to claim 57, wherein the immune response enhancer is selected from the group consisting of Montanide ISA50, Seppic Montanide ISA 720, a cytokine, a microsphere, dimethyl dioctadecyl ammoniumbromide (DDA) based adjuvants, AS-1, AS-2, Ribi Adjuvant system based adjuvant, QS21, saponin based adjuvants, Syntex adjuvant in its microfluidized form, MV, ddMV, immune stimulating complex (iscom) based adjuvants, and inactivated toxins.

60. (Previously Presented) The composition of claim 59, wherein said cytokine comprises GM-CSF.

61. (Withdrawn) An isolated polypeptide comprising a WT1 polypeptide, wherein the WT1 polypeptide comprises amino acids 1-249 of WT1 and wherein said WT1 polypeptide does not comprise full-length WT1.

62. (Withdrawn) An immunogenic composition comprising the isolated polypeptide of claim 61 in combination with a non-specific immune response enhancer, wherein the non-specific immune response enhancer preferentially enhances a T cell response in a patient.

63. (New) An immunogenic composition comprising an isolated polypeptide comprising a WT1 polypeptide, wherein the WT1 polypeptide comprises at least the amino acid sequence set forth in SEQ ID NO:144, and wherein the WT1 polypeptide does not comprise full-length WT1, in combination with a non-specific immune response enhancer, wherein the non-specific immune response enhancer preferentially enhances a T cell response in a patient.